NFE2L2 and cancer: DDRGK1 knockdown results in increased Nrf2 degradation and decreased Nrf2 stability, leading to an increase in ROS levels, which subsequently facilitates the apoptosis of cancer cells and heightens their sensitivity to chemotherapeutic agents, such as doxorubicin and etoposide.